Menkes Disease (MD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Menkes disease (MD) is a lethal multisystemic disorder of copper metabolism. The main manifestations are progressive neurodegeneration, connective tissue disturbances, and peculiar ‘kinky’ hair. MD is inherited as an X-linked recessive trait; as expected, most patients are men. MD is caused by mutations in the ATP7A gene, with most ATP7A mutations being intragenic or partial gene deletions. ATP7A is an energy-dependent transmembrane protein that transports copper to secreted copper enzymes and exports excess copper from cells. MD patients who are severely affected usually die before their third year of life. There is no cure for the disease, but very early copper-histidine treatment may alleviate some neurological symptoms.
·
Menkes disease (MD) is a rare condition with
incidence estimates ranging from 0.75 to 1.27 cases per 100,000 live births in
the USA. It is an inborn disorder of copper metabolism with multisystem
ramifications.
Thelansis’s “Menkes Disease (MD)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Menkes
Disease (MD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Menkes Disease (MD) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Menkes Disease (MD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment